United Therapeutics at JPMorgan Healthcare Conference: IPF and Super-Prostacyclin Focus

martes, 13 de enero de 2026, 2:29 am ET1 min de lectura
UTHR--

United Therapeutics CEO Dr. Martine Rothblatt discussed the company's focus on pulmonary fibrosis (IPF) and super-prostacyclin treatments at the JPMorgan Healthcare Conference. Rothblatt emphasized the significance of these two areas for the company, which aims to improve treatment options for patients with these conditions.

United Therapeutics at JPMorgan Healthcare Conference: IPF and Super-Prostacyclin Focus

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios